Daiichi Sankyo Vanflyta + chemotherapy as the first-line treatment of FLT3-ITD positive AML significantly prolongs survival

Daiichi Sankyo (Daiichi Sankyo) recently announced the positive top-line results of a key global phase 3 trial of QuANTUM-First

The results showed that the QuANTUM-First trial reached the primary endpoint: Compared with patients who received only standard treatment, patients who received Vanflyta+ standard induction and consolidation chemotherapy and then continued to receive Vanflyta monotherapy had a statistically significant overall survival (OS) And the improvement of clinical significance

AML is one of the most common leukemias in adults, accounting for about one-third of all cases

The data from the QuANTUM-First trial will be announced at an upcoming medical conference and will be shared with regulatory agencies

Molecular structure of quizartinib (picture source: Wikipedia)

Vanflyta’s active pharmaceutical ingredient, quizartinib, is a second-generation FLT3 inhibitor, which is an oral small molecule receptor tyrosine kinase inhibitor that selectively targets and inhibits FLT3

Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow that causes the uncontrolled proliferation and accumulation of dysfunctional cancerous white blood cells in the patient's body and affects the production of normal blood cells

FLT3 gene mutation can drive oncogenic signals and is one of the most common genetic abnormalities in AML.

In June 2019, Vanflyta received the world's first regulatory approval in Japan for the treatment of adult patients with relapsed/refractory FLT3-ITD-positive AML

Original source: Quizartinib Added to Chemotherapy Demonstrates Superior Overall Survival Compared to Chemotherapy Alone in Adult Patients with Newly Diagnosed FLT3-ITD Positive AML